Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | hu14.18-IL2 |
Trade Name | |
Synonyms | Lorukafusp alfa|EMD-273063|EMD 273063|APN301|APN-301|APN 301 |
Drug Descriptions |
Hu14.18-IL2 (Lorukafusp alfa) is a fusion protein comprised of a monoclonal antibody targeting the GD2 disialoganglioside linked to interleukin-2, which may inhibit growth of and induce an immune response against GD2-expressing tumors (PMID: 22844125, PMID: 20921469, PMID: 30073390). |
DrugClasses | |
CAS Registry Number | 2131168-99-3 |
NCIT ID | C162537 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
hu14.18-IL2 | hu14.18-IL2 | 0 | 2 |
hu14.18-IL2 + Ipilimumab + Nivolumab | Ipilimumab Nivolumab hu14.18-IL2 | 0 | 1 |
hu14.18-IL2 + Nivolumab | Nivolumab hu14.18-IL2 | 0 | 1 |